Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
A phase 2 trial of Teniposide, Etoposide, Serplulimab and Cisplatin in Small-cell lung cancer, run by Sun Yat-sen University, now recruiting.
Overview
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study is a phase 2 interventional study registered as NCT07583511 by Sun Yat-sen University, with 90 participants planned, started 2024-02-01 and due to reach its primary completion in 2027-05-01. Interventions recorded: Teniposide, Etoposide, serplulimab, cisplatin. Conditions recorded: Small-cell Lung Cancer.
Linked to the drug Teniposide because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTreatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin
Shares Teniposide, Cisplatin and the tag pipeline.
- TrialA Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
Shares Etoposide, Cisplatin, Small-cell lung cancer and the tag pipeline.
- TrialPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Shares Etoposide, Small-cell lung cancer and the tag pipeline.
- TrialPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Shares Etoposide, Cisplatin, Small-cell lung cancer and the tag pipeline.
- TrialA Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
- TrialA Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
Shares Etoposide, Small-cell lung cancer and the tag pipeline.
- TrialA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Shares Serplulimab and the tag pipeline.
- TrialA Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
Shares Serplulimab and the tag pipeline.